Pharmaceutical

Apollo Therapeutics secures $226.5m to advance pipeline programmes

Portfolio biopharmaceutical company Apollo Therapeutics has secured $226.5m in a Series C funding round to advance its pipeline of programmes.

Sep 7, 2023 - 20:00
Apollo Therapeutics secures $226.5m to advance pipeline programmes
Portfolio biopharmaceutical company Apollo Therapeutics has secured $226.5m in a Series C funding round to advance its pipeline of programmes.
Read the original article

Tags:

Previous Article

Novo Nordisk and Broad Institute to explore drug targets for diabetes, CMDs 

Next Article

Signal: Nimbus raises $210m to foster drug discovery plans

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: An accidental data release by Roche boosts some hopes for anti-TIGIT cancer immunotherapies

STAT+: An accidental data release by Roche boosts some ...

Aug 23, 2023

STAT+: Damages from tornado at Pfizer plant could compound challenges of drug shortages

STAT+: Damages from tornado at Pfizer plant could compo...

Jul 20, 2023

Blockchain leaders finesse tech to find fake drugs

Blockchain leaders finesse tech to find fake drugs

Sep 30, 2024